Skip to main content

Syngenta seeks collaborations in the field of gene technology

| News

Syngenta seeks collaborations in the field of gene technology


The Basel-based agricultural company Syngenta is seeking to grant the international research community access to some of its gene and breeding technologies. It is hoped that such collaborations can help to advance agricultural innovations.

DNA is extracted from plants in a laboratory (image: Syngenta)

Syngenta is inviting the international research community to collaborate on new agricultural technologies. In this context, the Basel-based agricultural company is offering the chance for researchers to secure the rights to some of its technologies based on the CRISPR-Cas12a gene scissors as well as breeding technologies. To this end, it is using its collaborative innovation platform Shoots by Syngenta.

With the CRISPR-Cas12a gene scissors, certain aspects of the genetic makeup of plants can be modified in a way that ensures diseases can be eliminated and specific positive properties are enhanced. “The power of CRISPR technology has incredible potential to enable crop innovation to deliver value to farmers”, comments Gusui Wu, Head of Global Seeds Research at Syngenta, in a press release issued by the company.

Partnerships drive innovations

Syngenta launched the Shoots by Syngenta platform in 2023. This is intended to facilitate new partnerships and, through these, drive innovations in the agricultural space. To license the technologies, Syngenta put in place a “simple, streamlined process”, as it explains in the press release. The technologies available are listed in an online catalog on the Shoots by Syngenta website.

According to the press release, Syngenta has a long and committed track record of collaborating with external research institutions. It was in this way that the company’s vegetable licensing platform was created, which enables breeding companies and academic institutes to access Syngenta germplasm for use in their breeding activities.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.